Company news
Caribou Biosciences, Inc. news in 2022
Caribou Biosciences, Inc.'s news releases, calls and decks from 2022, newest first.
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy
December 11, 2022
Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress
December 11, 2022
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
November 28, 2022
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
November 20, 2022
Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 7, 2022
Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting
November 2, 2022
Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022
October 17, 2022
Caribou Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
August 8, 2022
Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress
June 9, 2022
Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022
May 31, 2022
Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA Genome-Editing Technology in Primary Human T cells
May 15, 2022
Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
May 11, 2022
Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors
May 10, 2022
Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates
May 8, 2022
Caribou Biosciences to Present at Upcoming Investor Conference
May 2, 2022
Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)
May 1, 2022
Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress
April 24, 2022
Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting
April 7, 2022
Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 20, 2022
Caribou Biosciences to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
March 7, 2022
Caribou Biosciences to Present at Upcoming Investor Conferences
March 6, 2022
Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference
February 6, 2022
Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer
January 17, 2022
Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022
Decks in 2022
- Technical Presentation (June 2022)
Technical · 31 slides · Jun 10, 2022
- Corporate Update (May 2022)
Corporate update · 19 slides · May 12, 2022